Does the media prefer NBP or RIGL?

In the previous week, I-Mab had 4 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 17 mentions for I-Mab and 13 mentions for Rigel Pharmaceuticals. Rigel Pharmaceuticals' average media sentiment score of 1.19 beat I-Mab's score of 0.67 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment I-Mab 1 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rigel Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, NBP or FTH?

I-Mab is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio I-Mab N/A N/A -$46.27M -$0.36 N/A Sensei Biotherapeutics N/A N/A -$21.08M -$141.65 N/A

Is NBP or FTH more profitable?

I-Mab's return on equity of 0.00% beat Sensei Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets I-Mab N/A N/A N/A Sensei Biotherapeutics N/A -1,012.17% -175.69%

Does the media prefer NBP or FTH?

In the previous week, I-Mab had 12 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 17 mentions for I-Mab and 5 mentions for Sensei Biotherapeutics. I-Mab's average media sentiment score of 0.67 beat Sensei Biotherapeutics' score of 0.32 indicating that I-Mab is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment I-Mab 1 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sensei Biotherapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, NBP or PHAR?

Pharming Group has higher revenue and earnings than I-Mab. I-Mab is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio I-Mab N/A N/A -$46.27M -$0.36 N/A Pharming Group $376.13M 2.16 $2.85M $0.12 95.50

Which has better earnings & valuation, NBP or AURA?

I-Mab is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio I-Mab N/A N/A -$46.27M -$0.36 N/A Aura Biosciences N/A N/A -$106.19M -$1.75 N/A

Is NBP or AURA more profitable?

I-Mab's return on equity of 0.00% beat Aura Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets I-Mab N/A N/A N/A Aura Biosciences N/A -73.18% -62.00%

Does the media prefer NBP or AURA?

In the previous week, I-Mab had 16 more articles in the media than Aura Biosciences. MarketBeat recorded 17 mentions for I-Mab and 1 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 1.03 beat I-Mab's score of 0.67 indicating that Aura Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment I-Mab 1 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aura Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, NVCT or NBP?

Nuvectis Pharma is trading at a lower price-to-earnings ratio than I-Mab, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuvectis Pharma N/A N/A -$26.44M -$1.31 N/A I-Mab N/A N/A -$46.27M -$0.36 N/A

Is NVCT or NBP more profitable?

I-Mab's return on equity of 0.00% beat Nuvectis Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Nuvectis Pharma N/A -184.25% -105.24% I-Mab N/A N/A N/A

Does the media favor NVCT or NBP?

In the previous week, I-Mab had 14 more articles in the media than Nuvectis Pharma. MarketBeat recorded 17 mentions for I-Mab and 3 mentions for Nuvectis Pharma. Nuvectis Pharma's average media sentiment score of 0.69 beat I-Mab's score of 0.67 indicating that Nuvectis Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvectis Pharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive I-Mab 1 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

I-Mab (NBP) Competitors

$1.89 -0.11 (-5.50%)

Closing price 04:00 PM Eastern

Extended Trading

$1.88 0.00 (-0.26%)

As of 04:15 PM Eastern

Compare

NBP vs. RIGL, FTH, PHAR, AURA, and NVCT

Should you buy I-Mab stock or one of its competitors? I-Mab's main competitors and comparable companies include Rigel Pharmaceuticals (RIGL), Sensei Biotherapeutics (FTH), Pharming Group (PHAR), Aura Biosciences (AURA), and Nuvectis Pharma (NVCT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does I-Mab compare to Rigel Pharmaceuticals?

I-Mab (NASDAQ:NBP) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, earnings, media sentiment, risk, profitability, analyst recommendations and dividends.

38.4% of I-Mab shares are owned by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. 22.1% of I-Mab shares are owned by insiders. Comparatively, 10.5% of Rigel Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

I-Mab currently has a consensus price target of $9.00, indicating a potential upside of 376.19%. Rigel Pharmaceuticals has a consensus price target of $59.00, indicating a potential upside of 30.79%. Given I-Mab's higher probable upside, equities research analysts plainly believe I-Mab is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
I-Mab	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Rigel Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, I-Mab had 4 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 17 mentions for I-Mab and 13 mentions for Rigel Pharmaceuticals. Rigel Pharmaceuticals' average media sentiment score of 1.19 beat I-Mab's score of 0.67 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
I-Mab	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rigel Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rigel Pharmaceuticals has higher revenue and earnings than I-Mab. I-Mab is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
I-Mab	N/A	N/A	-$46.27M	-$0.36	N/A
Rigel Pharmaceuticals	$276.79M	3.02	$367.02M	$16.32	2.76

I-Mab has a beta of 1.47, meaning that its share price is 47% more volatile than the broader market. Comparatively, Rigel Pharmaceuticals has a beta of 1.16, meaning that its share price is 16% more volatile than the broader market.

Rigel Pharmaceuticals has a net margin of 116.30% compared to I-Mab's net margin of 0.00%. Rigel Pharmaceuticals' return on equity of 22.95% beat I-Mab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
I-Mab	N/A	N/A	N/A
Rigel Pharmaceuticals	116.30%	22.95%	17.19%

Summary

Rigel Pharmaceuticals beats I-Mab on 11 of the 15 factors compared between the two stocks.

How does I-Mab compare to Sensei Biotherapeutics?

I-Mab (NASDAQ:NBP) and Sensei Biotherapeutics (NASDAQ:FTH) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations.

38.4% of I-Mab shares are owned by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are owned by institutional investors. 22.1% of I-Mab shares are owned by company insiders. Comparatively, 7.0% of Sensei Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, I-Mab had 12 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 17 mentions for I-Mab and 5 mentions for Sensei Biotherapeutics. I-Mab's average media sentiment score of 0.67 beat Sensei Biotherapeutics' score of 0.32 indicating that I-Mab is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
I-Mab	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sensei Biotherapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

I-Mab has a beta of 1.47, meaning that its share price is 47% more volatile than the broader market. Comparatively, Sensei Biotherapeutics has a beta of -0.25, meaning that its share price is 125% less volatile than the broader market.

I-Mab's return on equity of 0.00% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
I-Mab	N/A	N/A	N/A
Sensei Biotherapeutics	N/A	-1,012.17%	-175.69%

I-Mab is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
I-Mab	N/A	N/A	-$46.27M	-$0.36	N/A
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$141.65	N/A

I-Mab presently has a consensus target price of $9.00, indicating a potential upside of 376.19%. Sensei Biotherapeutics has a consensus target price of $55.00, indicating a potential upside of 58.46%. Given I-Mab's higher possible upside, equities research analysts clearly believe I-Mab is more favorable than Sensei Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
I-Mab	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Sensei Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

Summary

I-Mab beats Sensei Biotherapeutics on 9 of the 14 factors compared between the two stocks.

How does I-Mab compare to Pharming Group?

I-Mab (NASDAQ:NBP) and Pharming Group (NASDAQ:PHAR) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

In the previous week, I-Mab had 17 more articles in the media than Pharming Group. MarketBeat recorded 17 mentions for I-Mab and 0 mentions for Pharming Group. I-Mab's average media sentiment score of 0.67 beat Pharming Group's score of 0.00 indicating that I-Mab is being referred to more favorably in the media.

Company	Overall Sentiment
I-Mab	Positive
Pharming Group	Neutral

I-Mab has a beta of 1.47, indicating that its stock price is 47% more volatile than the broader market. Comparatively, Pharming Group has a beta of -0.01, indicating that its stock price is 101% less volatile than the broader market.

38.4% of I-Mab shares are held by institutional investors. Comparatively, 0.0% of Pharming Group shares are held by institutional investors. 22.1% of I-Mab shares are held by insiders. Comparatively, 2.1% of Pharming Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

I-Mab presently has a consensus price target of $9.00, indicating a potential upside of 376.19%. Pharming Group has a consensus price target of $38.67, indicating a potential upside of 237.41%. Given I-Mab's higher possible upside, equities research analysts clearly believe I-Mab is more favorable than Pharming Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
I-Mab	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Pharming Group	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Pharming Group has higher revenue and earnings than I-Mab. I-Mab is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
I-Mab	N/A	N/A	-$46.27M	-$0.36	N/A
Pharming Group	$376.13M	2.16	$2.85M	$0.12	95.50

Pharming Group has a net margin of 2.51% compared to I-Mab's net margin of 0.00%. Pharming Group's return on equity of 3.40% beat I-Mab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
I-Mab	N/A	N/A	N/A
Pharming Group	2.51%	3.40%	1.90%

Summary

Pharming Group beats I-Mab on 9 of the 15 factors compared between the two stocks.

How does I-Mab compare to Aura Biosciences?

I-Mab (NASDAQ:NBP) and Aura Biosciences (NASDAQ:AURA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings.

I-Mab has a beta of 1.47, indicating that its share price is 47% more volatile than the broader market. Comparatively, Aura Biosciences has a beta of 0.4, indicating that its share price is 60% less volatile than the broader market.

I-Mab presently has a consensus target price of $9.00, indicating a potential upside of 376.19%. Aura Biosciences has a consensus target price of $17.50, indicating a potential upside of 121.52%. Given I-Mab's higher probable upside, research analysts clearly believe I-Mab is more favorable than Aura Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
I-Mab	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aura Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, I-Mab had 16 more articles in the media than Aura Biosciences. MarketBeat recorded 17 mentions for I-Mab and 1 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 1.03 beat I-Mab's score of 0.67 indicating that Aura Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
I-Mab	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aura Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

I-Mab is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
I-Mab	N/A	N/A	-$46.27M	-$0.36	N/A
Aura Biosciences	N/A	N/A	-$106.19M	-$1.75	N/A

38.4% of I-Mab shares are held by institutional investors. Comparatively, 96.8% of Aura Biosciences shares are held by institutional investors. 22.1% of I-Mab shares are held by company insiders. Comparatively, 1.9% of Aura Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

I-Mab's return on equity of 0.00% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
I-Mab	N/A	N/A	N/A
Aura Biosciences	N/A	-73.18%	-62.00%

Summary

I-Mab beats Aura Biosciences on 8 of the 13 factors compared between the two stocks.

How does I-Mab compare to Nuvectis Pharma?

Nuvectis Pharma (NASDAQ:NVCT) and I-Mab (NASDAQ:NBP) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability.

In the previous week, I-Mab had 14 more articles in the media than Nuvectis Pharma. MarketBeat recorded 17 mentions for I-Mab and 3 mentions for Nuvectis Pharma. Nuvectis Pharma's average media sentiment score of 0.69 beat I-Mab's score of 0.67 indicating that Nuvectis Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvectis Pharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
I-Mab	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nuvectis Pharma presently has a consensus price target of $35.00, indicating a potential upside of 46.63%. I-Mab has a consensus price target of $9.00, indicating a potential upside of 376.19%. Given I-Mab's higher possible upside, analysts clearly believe I-Mab is more favorable than Nuvectis Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
I-Mab	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

96.8% of Nuvectis Pharma shares are held by institutional investors. Comparatively, 38.4% of I-Mab shares are held by institutional investors. 28.6% of Nuvectis Pharma shares are held by insiders. Comparatively, 22.1% of I-Mab shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Nuvectis Pharma has a beta of -0.26, indicating that its share price is 126% less volatile than the broader market. Comparatively, I-Mab has a beta of 1.47, indicating that its share price is 47% more volatile than the broader market.

I-Mab's return on equity of 0.00% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvectis Pharma	N/A	-184.25%	-105.24%
I-Mab	N/A	N/A	N/A

Nuvectis Pharma is trading at a lower price-to-earnings ratio than I-Mab, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A
I-Mab	N/A	N/A	-$46.27M	-$0.36	N/A

Summary

I-Mab beats Nuvectis Pharma on 7 of the 13 factors compared between the two stocks.

Get I-Mab News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NBP vs. The Competition

Export

Metric	I-Mab	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$218.58M	$3.99B	$7.29B	$12.71B
Dividend Yield	N/A	3.64%	2.54%	10.79%
P/E Ratio	-5.25	11.78	271.39	24.10
Price / Sales	N/A	1,299.82	604.58	77.05
Price / Cash	N/A	44.94	29.03	36.90
Price / Book	0.95	17.27	11.18	6.40
Net Income	-$46.27M	-$22.72M	$3.46B	$348.28M
7 Day Performance	-2.07%	2.91%	1.98%	0.92%
1 Month Performance	6.78%	9.75%	7.32%	5.10%
1 Year Performance	N/A	54.82%	24.76%	16.16%

I-Mab Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NBP I-Mab	2.2362 of 5 stars	$1.89 -5.5%	$9.00 +376.2%	N/A	$218.58M	N/A	N/A	380	News Coverage Earnings Report Analyst Upgrade Analyst Revision
RIGL Rigel Pharmaceuticals	4.5659 of 5 stars	$45.89 +1.4%	$59.00 +28.6%	+10.6%	$837.22M	$294.28M	2.81	160	Positive News
FTH Sensei Biotherapeutics	4.3734 of 5 stars	$32.00 -0.3%	$55.00 +71.9%	N/A	$829.48M	N/A	N/A	40	News Coverage Analyst Forecast Gap Up
PHAR Pharming Group	3.7205 of 5 stars	$11.85 +1.5%	$38.67 +226.3%	-13.5%	$826.69M	$366.48M	98.75	280
AURA Aura Biosciences	2.1549 of 5 stars	$7.80 +0.4%	$17.50 +124.4%	+19.1%	$805.79M	N/A	N/A	50

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NBP) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

I-Mab (NBP) Competitors

NBP vs. RIGL, FTH, PHAR, AURA, and NVCT

How does I-Mab compare to Rigel Pharmaceuticals?

Summary

How does I-Mab compare to Sensei Biotherapeutics?

Summary

How does I-Mab compare to Pharming Group?

Summary

How does I-Mab compare to Aura Biosciences?

Summary

How does I-Mab compare to Nuvectis Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBP vs. The Competition

I-Mab Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

I-Mab (NBP) Competitors

NBP vs. RIGL, FTH, PHAR, AURA, and NVCT

How does I-Mab compare to Rigel Pharmaceuticals?

Do insiders & institutionals have more ownership in NBP or RIGL?

Do analysts rate NBP or RIGL?

Does the media prefer NBP or RIGL?

Which has higher earnings and valuation, NBP or RIGL?

Which has more risk & volatility, NBP or RIGL?

Is NBP or RIGL more profitable?

Summary

How does I-Mab compare to Sensei Biotherapeutics?

Do institutionals and insiders have more ownership in NBP or FTH?

Does the media prefer NBP or FTH?

Which has more risk and volatility, NBP or FTH?

Is NBP or FTH more profitable?

Which has preferable earnings & valuation, NBP or FTH?

Do analysts rate NBP or FTH?

Summary

How does I-Mab compare to Pharming Group?

Does the media prefer NBP or PHAR?

Which has more volatility & risk, NBP or PHAR?

Do institutionals & insiders believe in NBP or PHAR?

Do analysts recommend NBP or PHAR?

Which has stronger earnings and valuation, NBP or PHAR?

Is NBP or PHAR more profitable?

Summary

How does I-Mab compare to Aura Biosciences?

Which has more volatility and risk, NBP or AURA?

Do analysts prefer NBP or AURA?

Does the media prefer NBP or AURA?

Which has better earnings & valuation, NBP or AURA?

Do insiders & institutionals believe in NBP or AURA?

Is NBP or AURA more profitable?

Summary

How does I-Mab compare to Nuvectis Pharma?

Does the media favor NVCT or NBP?

Do analysts recommend NVCT or NBP?

Do insiders & institutionals hold more shares of NVCT or NBP?

Which has more risk & volatility, NVCT or NBP?

Is NVCT or NBP more profitable?

Which has better valuation and earnings, NVCT or NBP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBP vs. The Competition

I-Mab Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools